---
title: "Understanding the Market | HANSOH PHARMA opened nearly 2% higher, Goldman Sachs believes the company can promote or commercialize HS-10535 jointly in mainland China and Hong Kong-Macau or separately"
description: "HANSOH PHARMA's stock price opened nearly 2% higher and, as of the time of writing, has risen 1.96% to HKD 18.7. Goldman Sachs released a report stating that HANSOH PHARMA has signed a global exclusiv"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/222869020.md"
published_at: "2024-12-20T01:30:05.000Z"
---

# Understanding the Market | HANSOH PHARMA opened nearly 2% higher, Goldman Sachs believes the company can promote or commercialize HS-10535 jointly in mainland China and Hong Kong-Macau or separately

> HANSOH PHARMA's stock price opened nearly 2% higher and, as of the time of writing, has risen 1.96% to HKD 18.7. Goldman Sachs released a report stating that HANSOH PHARMA has signed a global exclusive licensing agreement with Merck & Co. to obtain the sales rights for the oral GLP-1 drug HS-10535. Goldman Sachs believes that the company can promote this product in mainland China and Hong Kong and Macau, and is optimistic about the global potential of its innovative product line. HANSOH PHARMA's GLP-1 product portfolio is comprehensive, with another oral GLP-1 drug HS-10501 already in clinical trials

According to Zhitong Finance APP, HANSOH PHARMA (03692) opened nearly 2% higher, and as of the time of writing, it rose 1.96% to HKD 18.7, with a transaction volume of HKD 1.9591 million.

Goldman Sachs released a research report stating that HANSOH PHARMA announced on December 18th a global exclusive licensing agreement with Merck for the global sales rights of the oral GLP-1 small molecule drug HS-10535, involving an upfront payment of USD 112 million, milestone payments of USD 1.9 billion, and royalties based on product sales. Goldman Sachs believes that HANSOH PHARMA can jointly promote or independently commercialize this product in mainland China and Hong Kong and Macau.

The firm noted that this is the second collaboration with a multinational company for HANSOH PHARMA in the past two years, having previously licensed two ADC drugs to GSK. The firm views positively the growing global potential of the company's innovative product line. Due to the increasing competition for oral GLP-1 drugs, Goldman Sachs has observed that more latecomers are attempting to seek differentiation in target selection and indication development. However, HANSOH PHARMA has developed a comprehensive GLP-1 product portfolio that includes both injectable and oral drugs, with another oral GLP-1 (HS-10501) already entering Phase I clinical trials. Goldman Sachs believes this drug also has licensing potential. The company plans to conduct Phase II studies in the first half of 2025

### Related Stocks

- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)
- [600867.CN - THDB](https://longbridge.com/en/quote/600867.CN.md)
- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)
- [300199.CN - HYBIO](https://longbridge.com/en/quote/300199.CN.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)
- [GS.US - Goldman Sachs](https://longbridge.com/en/quote/GS.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 翰森制药宣布，甲磺酸奥莫替尼片在欧盟获批用于单药治疗 | 汉森制药集团有限公司：AUMOLERTINIB 美克替尼片在欧盟作为单药治疗获得批准 | [Link](https://longbridge.com/en/news/276401882.md) |
| 翰森制药的关键肺癌药物奥莫替尼获得欧盟批准 | 翰森制药获得欧盟对关键肺癌药物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |
| 加拿大宣布新国防工业战略，注重国内制造以重获战备能力 | 加拿大总理卡尼于 2 月 17 日宣布新的国防工业战略，设定未来十年目标，包括将 70% 的国防合同授予本国企业，旨在实现国内采购和维护大部分军事装备。 | [Link](https://longbridge.com/en/news/276178964.md) |
| 贝森特和沃什的 “导师”，德鲁肯米勒 Q4“精准” 开仓金融股 ETF、标普等权重 ETF 和巴西 ETF | 科技股方面，德鲁肯米勒 Q4 清仓了 Meta，加仓了谷歌与 Sea。德鲁肯米勒与贝森特、沃什的 “师徒” 关系让市场推测，“德鲁肯米勒经济学”——即反赤字、反通胀、反关税——可能通过贝森特和沃什渗透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| 华尔街大佬 Tepper 押注 AI：美光持仓激增 200%，新买韩国 ETF | 对冲基金大佬 Tepper 去年四季度精准狙击 AI 芯片赛道，豪掷逾 6 亿美元重仓美光科技和韩国芯片 ETF，今年已斩获约 30% 回报。全球内存短缺叠加 AI 算力狂潮，其芯片押注与软件股暴跌形成冰火两重天。 | [Link](https://longbridge.com/en/news/276213747.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.